Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04969861
Title BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Nektar Therapeutics
Indications

oral squamous cell carcinoma

oropharynx cancer

head and neck squamous cell carcinoma

oral cavity cancer

laryngeal squamous cell carcinoma

hypopharynx cancer

Therapies

NKTR-214 + Pembrolizumab

Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | AUT


No variant requirements are available.